publication date: Mar. 30, 2017
Ovarian Cancer Olaparib phase III SOLO-2 trial demonstrates significant PFS benefit in BRCA-mutated disease
AstraZeneca presented data from the confirmatory Phase III SOLO-2 trial demonstrating a statistically significant and clinically meaningful improvement of progression-free survival among patients treated with Lynparza (olaparib) compared to placebo.
The results were presented at the 2017 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in National Harbor, Maryland. The SOLO-2 trial was designed to determine the efficacy of Lynparza tablets (300mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive relapsed, germline BRCA-mutated ovarian cancer.
Results from the trial provide additional evidence to support the use of Lynparza as a standard of care for patients with platinum-sensitive relapsed, BRCA-mutated ovarian cancer, and findings demonstrate that the efficacy and safety profile with Lynparza tablets was consistent with previous studies.
The trial met its primary endpoint and Lynparza demonstrated a 70 per cent reduced risk of progression based upon investigator assessed PFS. This means patients taking Lynparza as a maintenance therapy can have a much longer progression-free interval with no detriment to quality of life, compared to no treatment, which has been the traditional approach.
The result is further supported by the PFS as measured by the Blinded Independent Central Review (BICR) evaluation showing that the median PFS was over two years. See table below for … Continue reading CCL March 2017 – Olaparib phase III SOLO-2 trial demonstrates significant PFS benefit in BRCA-mutated disease
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.